Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP-308
- Development stage
- Preclinical
- Lead developer
- Alebund Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Parenteral
01
Overview
AP-308 is a recombinant biologic, specifically an Fc fusion protein, developed as an IgA protease inhibitor. It is designed to cleave and clear IgA deposits, primarily for the treatment of IgA nephropathy. The drug is based on an IgA protease (AK183) derived from the commensal bacterium Clostridium ramosum, which is fused to the Fc segment of human IgG1 to extend its half-life in blood. It aims to provide a targeted enzymatic strategy to remove IgA and associated complement C3 deposits in the glomerulus, addressing the underlying pathology of IgA nephropathy. It is currently in preclinical development.
- Other names
- Fc-AK183Fc-AK-183Fc-AK 183
02
Targets
IgA (Immunoglobulin A)
Beyond the preview
Go deeper on AP-308.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP-308.